COMPLEGENT
DEAD

Serial Number

77179157

Owner

KYOWA HAKKO KIRIN CO., LTD.

Attorney

Kaushal Odedra

Filing Date

May 11, 2007

Add to watchlist:

No watchlists yet
View on USPTO

COMPLEGENT Trademark

Serial Number: 77179157 • Registration: 3668133

COMPLEGENT is a trademark filed by KYOWA HAKKO KIRIN CO., LTD. on May 11, 2007. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

KYOWA HAKKO KIRIN CO., LTD. (58 trademarks)

1-6-1, OHTEMACHI, CHIYODA-KU
TOKYO , JP

Entity Type: 99

KYOWA HAKKO KOGYO CO., LTD. (51 trademarks)

CHIYODA-KU, TOKYO , JP

Entity Type: 03

KYOWA KIRIN CO., LTD. (47 trademarks)

TOKYO 100-0004 , JP

Entity Type: 03

Trademark Details

Filing Date

May 11, 2007

Registration Date

August 18, 2009

Published for Opposition

June 2, 2009

Cancellation Date

May 25, 2021

Goods & Services

Contract manufacturing service in the field of antibodies, fragments of antibodies, and derivatives of antibodies; contract manufacturing service in the field of cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; contract manufacturing service in the field of transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; [ contract manufacturing service in the field of host cells; contract extracting, refining, synthesizing, manufacturing and preparing pharmaceuticals, agricultural chemicals, and chemicals; ] providing information in the field of manufacturing technology in the field of antibodies, fragments of antibodies, and derivatives of antibodies; technical consultation in the field of manufacturing technology in the field of antibodies, fragments of antibodies, and derivatives of antibodies; providing information in the field of manufacturing technology in the field of cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; technical consultation in the field of manufacturing technology in the field of cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; providing information in the field of manufacturing technology in the field of transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies; technical consultation in the field of manufacturing technology in the field of transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies[ ; providing information in the field of manufacturing technology in the field of host cells; technical consultation in the field of manufacturing technology in the field of host cells; providing technical information in the field of extracting, refining, synthesizing, manufacturing and preparing pharmaceuticals, agricultural chemicals, and chemicals technical consultation in the field of extracting, refining, synthesizing, manufacturing and preparing pharmaceuticals, agricultural chemicals, and chemicals ]

[ Host cells for medical or clinical use; cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies for medical or clinical use; transfected cells that manufacture antibodies, fragments of antibodies or derivatives of antibodies for medical or clinical use; pharmaceuticals, namely, central nervous system depressants, preparations for ophthalmic use, anti-histaminics, cardiotonics, arrhythmia treating agents, diuretics, hypotensors, prophylactic for the treatment of asthma, antitussives and expectorants, stomachics and digestives, antacids, hormones, namely, pituitary hormones for the treatment of infertility, thyroid hormones for the treatment of hyperthyroidism, anabolic hormones for the treatment of aplastic anemia and osteoporosis, corticosteroids for treatment of hypopituitarism, congenital adrenal hyperplasia, rheumatoid arthritis, rheumatic fever, crohn's disease, and chronic active hepatitis, estrogen and progesterone used as combined oral contraceptives, urinary antiseptics, analgesics, anti-itching agents, cataplasms for the treatment of bruises, lumbago and stiff shoulder, pharmaceutical preparations used to treat hair disorders, vitamin preparations, food enriching agents for treating vitamin deficiencies, anti-coagulants, enzyme preparations for control of malabsorption and diarrhea, anti-cancer preparations, anti-sarcoma preparations, antibiotics and their preparations for the treatment of infectious diseases, antituberculotic agents, influenza vaccines, diphtheria vaccines, tetanus vaccines, gas gangrene vaccines, Japanese encephalitis vaccines, in vitro tetrodotoxines for medical use, antiprotozoals for the treatment of trichomoniasis and dermatophytosis, anthelmintics for the treatment of threadworm and toxoplasmaosis, naturally occurring drugs for treating peptic ulcers, charred drugs for treating peptic ulcers, moxa for treating peptic ulcers, veterinary drugs for the treatment of distemper in dogs, distomatosis in dogs, coccidian in chickens, and dysentery in pigs, germination controllers and plant rearing agents, namely, herbicides, fungicides, insecticides, bactericides and rodenticides for domestic and or agricultural use, antiseptics, drugs for arteriosclerosis, oncostatic drugs for the treatment for cancer, multienzyme digestants for in vivo use, antifungal antibiotics for treating trichomoniasis and dermatophytosis, anti parkinsonism drugs, minor tranquilizers, and anti anxiety agents, medicinal preparations for the treatment of the central nervous system, the respiratory tract and the cardiovascular system, anti-bacterial preparations, monolithic preparations, medicinal preparations for the treatment of peptic ulcers, anti-inflammatory preparations, analgesic preparations, cephalosporin, cocarboxylase preparations, glutathione preparations, preparations for improving the metabolism and the peripheral circulation, plasma substitutes and extracorporeal circulation flow improvement preparations, diuretic and anti-hypertensive preparations, in vitro diagnostic reagents for medical use, in vitro extra corporeal diagnostic reagents for medical use, in vitro x-ray contrast agents for medical use, in vitro diagnostic media, pharmaceutical preparations for the treatment of insomnia and other sleep related diseases ]

Development of new products for others in the field of antibodies, fragments of antibodies, derivatives of antibodies, cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, and host cells; providing technical information in the field of development of new products in the field of antibodies, fragments of antibodies, derivatives of antibodies, cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, and host cells; technical consultation in the field of development of new products in the field of antibodies, fragments of antibodies, derivatives of antibodies, cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies, transfected cells that manufacture antibodies, fragments of antibodies, and derivatives of antibodies[, and host cells ]

Filing History

NOTICE OF CANCELLATION SEC. 8 EMAILED
May 26, 2021 NCS8
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
May 25, 2021 APRE
CANCELLED SEC. 8 (10-YR)
May 25, 2021 C8.T
PETITION TO DIRECTOR DENIED
Apr 30, 2021 PCDE
ASSIGNED TO PETITION STAFF
Nov 2, 2020 APET
TEAS PETITION TO DIRECTOR RECEIVED
Jun 25, 2020 TPDR
POST REGISTRATION ACTION MAILED - SEC. 8 & 9
Apr 1, 2020 PR89
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
Mar 12, 2020 EROP
POST REGISTRATION ACTION MAILED - SEC. 8 & 9
Nov 4, 2019 PR89
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Sep 11, 2019 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Sep 11, 2019 REAP
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
Sep 11, 2019 EROP
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Sep 4, 2019 ASGN
POST REGISTRATION ACTION MAILED - SEC. 8 & 9
May 30, 2019 PR89
POST REGISTRATION ACTION MAILED - SEC. 8 & 9
May 30, 2019 PR89
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
May 16, 2019 APRE
TEAS SECTION 8 & 9 RECEIVED
Apr 8, 2019 E89R
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Aug 18, 2018 REM2
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
Sep 22, 2015 NAS8
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
Sep 22, 2015 NAS8
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED
Sep 22, 2015 8.PR
REGISTERED - SEC. 8 (6-YR) ACCEPTED
Sep 22, 2015 8.OK
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Sep 4, 2015 APRE
REGISTERED - SEC. 8 (6-YR) FILED
Aug 17, 2015 8.AF
TEAS SECTION 8 RECEIVED
Aug 17, 2015 ES8R
REGISTERED-PRINCIPAL REGISTER
Aug 18, 2009 R.PR
PUBLISHED FOR OPPOSITION
Jun 2, 2009 PUBO
NOTICE OF PUBLICATION
May 13, 2009 NPUB
LAW OFFICE PUBLICATION REVIEW COMPLETED
Apr 29, 2009 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 27, 2009 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 25, 2009 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 25, 2009 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Mar 25, 2009 ERSI
LETTER OF SUSPENSION MAILED
Mar 2, 2009 CNSL
SUSPENSION LETTER WRITTEN
Mar 1, 2009 CNSL
AMENDMENT FROM APPLICANT ENTERED
Feb 9, 2009 ACEC
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 9, 2009 CRFA
PAPER RECEIVED
Feb 6, 2009 MAIL
INQUIRY AS TO SUSPENSION MAILED
Jan 12, 2009 CNSI
SUSPENSION INQUIRY WRITTEN
Jan 11, 2009 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Jan 9, 2009 RCCK
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Nov 19, 2008 ASGN
LETTER OF SUSPENSION MAILED
Jul 9, 2008 CNSL
SUSPENSION LETTER WRITTEN
Jul 8, 2008 CNSL
AMENDMENT FROM APPLICANT ENTERED
Jun 11, 2008 ACEC
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 11, 2008 CRFA
PAPER RECEIVED
Jun 9, 2008 MAIL
INQUIRY AS TO SUSPENSION MAILED
Mar 26, 2008 CNSI
SUSPENSION INQUIRY WRITTEN
Mar 25, 2008 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Feb 24, 2008 RCCK
ASSIGNED TO LIE
Feb 24, 2008 ALIE
LETTER OF SUSPENSION MAILED
Aug 24, 2007 CNSL
SUSPENSION LETTER WRITTEN
Aug 24, 2007 CNSL
ASSIGNED TO EXAMINER
Aug 24, 2007 DOCK
NEW APPLICATION ENTERED
May 16, 2007 NWAP